Cargando…
Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
BACKGROUND: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320102/ https://www.ncbi.nlm.nih.gov/pubmed/25658921 http://dx.doi.org/10.1371/journal.pone.0118191 |
_version_ | 1782356061912563712 |
---|---|
author | Orikiriza, Patrick Tibenderana, Becky Siedner, Mark J. Mueller, Yolanda Byarugaba, Frederick Moore, Christopher C. Evans, Emily E. Bonnet, Maryline Page, Anne-Laure Bazira, Joel Boum II, Yap |
author_facet | Orikiriza, Patrick Tibenderana, Becky Siedner, Mark J. Mueller, Yolanda Byarugaba, Frederick Moore, Christopher C. Evans, Emily E. Bonnet, Maryline Page, Anne-Laure Bazira, Joel Boum II, Yap |
author_sort | Orikiriza, Patrick |
collection | PubMed |
description | BACKGROUND: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data to guide regional recommendations for empiric TB therapy. METHODS: Archived isolates, obtained from patients at Mbarara Regional Referral Hospital from February 2009 to February 2013, were tested for resistance to isoniazid and rifampicin using the MTBDRplus and Xpert MTB/RIF assays. A subset of randomly selected isolates was tested for second line agents, including fluoroquinolones (FQs), aminoglycosides, cyclic peptides, and ethambutol using the MTBDRsl assay. We performed confirmatory testing for FQ resistance using repeated MTBDRsl, the Mycobacteria growth indicator tube (MGIT) assay, and sequencing of the gyrA and gyrB genes. RESULTS: We tested isolates from 190 patients. The cohort had a median age of 33 years (IQR 26-43), 69% (131/190) were male, and the HIV prevalence was 42% (80/190). No isolates (0/190) were rifampicin-resistant and only 1/190 (0.5%) was isoniazid-resistant. Among 92 isolates tested for second-line drug resistance, 71 (77%) had interpretable results, of which none were resistant to aminoglycosides, cyclic peptides or ethambutol. Although 7 (10%) initially tested as resistant to FQs by the MTBDRsl assay, they were confirmed as susceptible by repeat MTBDRsl testing as well as by MGIT and gyrase gene sequencing CONCLUSION: We found no MDR-TB and no resistance to ethambutol, FQs, or injectable anti-TB drugs in treatment naïve patients with pulmonary TB in Southwestern Uganda. Standard treatment guidelines for susceptible TB should be adequate for most patients with TB in this population. Where possible, molecular susceptibility testing methods should be routinely validated by culture methods. |
format | Online Article Text |
id | pubmed-4320102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43201022015-02-18 Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda Orikiriza, Patrick Tibenderana, Becky Siedner, Mark J. Mueller, Yolanda Byarugaba, Frederick Moore, Christopher C. Evans, Emily E. Bonnet, Maryline Page, Anne-Laure Bazira, Joel Boum II, Yap PLoS One Research Article BACKGROUND: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data to guide regional recommendations for empiric TB therapy. METHODS: Archived isolates, obtained from patients at Mbarara Regional Referral Hospital from February 2009 to February 2013, were tested for resistance to isoniazid and rifampicin using the MTBDRplus and Xpert MTB/RIF assays. A subset of randomly selected isolates was tested for second line agents, including fluoroquinolones (FQs), aminoglycosides, cyclic peptides, and ethambutol using the MTBDRsl assay. We performed confirmatory testing for FQ resistance using repeated MTBDRsl, the Mycobacteria growth indicator tube (MGIT) assay, and sequencing of the gyrA and gyrB genes. RESULTS: We tested isolates from 190 patients. The cohort had a median age of 33 years (IQR 26-43), 69% (131/190) were male, and the HIV prevalence was 42% (80/190). No isolates (0/190) were rifampicin-resistant and only 1/190 (0.5%) was isoniazid-resistant. Among 92 isolates tested for second-line drug resistance, 71 (77%) had interpretable results, of which none were resistant to aminoglycosides, cyclic peptides or ethambutol. Although 7 (10%) initially tested as resistant to FQs by the MTBDRsl assay, they were confirmed as susceptible by repeat MTBDRsl testing as well as by MGIT and gyrase gene sequencing CONCLUSION: We found no MDR-TB and no resistance to ethambutol, FQs, or injectable anti-TB drugs in treatment naïve patients with pulmonary TB in Southwestern Uganda. Standard treatment guidelines for susceptible TB should be adequate for most patients with TB in this population. Where possible, molecular susceptibility testing methods should be routinely validated by culture methods. Public Library of Science 2015-02-06 /pmc/articles/PMC4320102/ /pubmed/25658921 http://dx.doi.org/10.1371/journal.pone.0118191 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Orikiriza, Patrick Tibenderana, Becky Siedner, Mark J. Mueller, Yolanda Byarugaba, Frederick Moore, Christopher C. Evans, Emily E. Bonnet, Maryline Page, Anne-Laure Bazira, Joel Boum II, Yap Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda |
title | Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda |
title_full | Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda |
title_fullStr | Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda |
title_full_unstemmed | Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda |
title_short | Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda |
title_sort | low resistance to first and second line anti-tuberculosis drugs among treatment naive pulmonary tuberculosis patients in southwestern uganda |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320102/ https://www.ncbi.nlm.nih.gov/pubmed/25658921 http://dx.doi.org/10.1371/journal.pone.0118191 |
work_keys_str_mv | AT orikirizapatrick lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT tibenderanabecky lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT siednermarkj lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT muelleryolanda lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT byarugabafrederick lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT moorechristopherc lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT evansemilye lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT bonnetmaryline lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT pageannelaure lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT bazirajoel lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda AT boumiiyap lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda |